PharmaShots | Incisive News in 3 Shots

Subscribe Now

Depression

Compass Pathways' Psilocybin Therapy Receives FDA's Breakthrough Therapy Designation for Treatment-Resistant Depression

Compass Pathways' Psilocybin Therapy Receives FDA's Breakthrough Therapy Designation for Treatment-Resistant Depression

October 23, 2018

FDA Reports Newly Added Guidelines for Drug and Device Makers

FDA Reports Newly Added Guidelines for Drug and Device Makers

August 31, 2018

Neurocrine Biosciences Reports Positive Results from P-II study of NBI-1065845 in MDD

Neurocrine Biosciences Reports Positive Results from P-II study of NBI-1065845 in MDD

April 24, 2024

Neurocrine Biosciences Doses First Patient with NBI-1070770 in P-II Trial for Treating Major Depressive Disorder

Neurocrine Biosciences Doses First Patient with NBI-1070770 in P-II Trial for Treating Major Depressive Disorder

April 4, 2024

GH Research’s Mebufotenin (5-MeO-DMT) and its Salt Products Receive European Patent for Major Depressive Disorder and Treatment-Resistant Depression

GH Research’s Mebufotenin (5-MeO-DMT) and its Salt Products Receive European Patent for Major Depressive Disorder and Treatment-Re...

January 19, 2024

MIRA Pharmaceuticals & MIRALOGX Entered into an Exclusive Licensing Agreement for Ketamir-2

MIRA Pharmaceuticals & MIRALOGX Entered into an Exclusive Licensing Agreement for Ketamir-2

November 21, 2023

Insights+: The US FDA New Drug Approvals in August 2023

Insights+: The US FDA New Drug Approvals in August 2023

September 20, 2023

Cybin to Acquire Small Pharma and Create an International Clinical-Stage Leader in Novel Psychedelic Therapeutics

Cybin to Acquire Small Pharma and Create an International Clinical-Stage Leader in Novel Psychedelic Therapeutics

August 29, 2023

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us